Diagnosis of cancer-associated vascular disorders

Cancer

Volumn 77, Issue 9, 1996, Pages 1759-1767

  Naschitz, Jochanan E ^a,b   Yeshurun, Daniel ^a   Eldar, Samuel ^a   Lev, Louise M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

cancer; paraneoplastic; thrombosis; vasculopathy

Indexed keywords

TUMOR MARKER;

ANTIGEN SPECIFICITY; CANCER DIAGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HUMAN; INCIDENCE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0029912170     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1759::AID-CNCR1>3.0.CO;2-7     Document Type: Review

References (110)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. Volume 3. London: New Sydenham Society, 1865:695-727.
2. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic and therapeutic features. Medicine (Baltimore) 1977;56:1-37.
3. Rickles FR, Edward RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Cancer 1983;51:301-7.
4. Bell WR, Starksen NF, Portfield JK. Trousseau's syndrome: devastating coagulopathy in the absence of heparin. Am J Med 1985;79:423-30.
5. Goldsmith GH Jr. Hemostatic disorders associated with neoplasia. Forbes CD, Ratnoff OD, editors. Disorders of hemostasis. Philadelphia: Grune & Stratton, 1984:351-66.
6. Edwards EA. Migratory thrombophlebitis associated with carcinoma. N Engl J Med 1947;240:1031-4.
7. Lieberman JS, Borrero J, Urrdeaneta E, Wright IS. Thrombophlebitis and cancer. JAMA 1961;177:542-5.
8. Nussbacher J. Migratory venous thrombosis of legs. N Y State J Med 1964;64:2166-73.
9. Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with deep venous thrombosis. Arch Intern Med 1987;147:556-60.
10. Goldberg RJ, Seneff M, Gore JM. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987;147:251-3.
11. Griffin MR, Stanson AW, Brown ML, Hauser MF, O'Fallon M, Anderson HM, et al. Deep venous thrombosis and pulmonary embolism: risk of subsequent malignant neoplasia. Arch Intern Med 1987;147:1907-11.
12. Bunn PA Jr. Paraneoplastic syndromes. DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott, 1982:1476-1517.
13. Donati MB. Cancer and thrombosis. Haemostasis 1994;24: 128-31.
14. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993;119:819-27.
15. Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy: experience with 13 patients and literature review. Medicine (Baltimore) 1988;67: 222-30.
16. Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A, Reyes E, Iglesias A, Alarcon-Segovia D. Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. J Rheumatol 1990;17:1458-62.
17. Escalante CP. Causes and management of superior vena cava syndrome. Oncology (Huntingt) 1993;7:61-8.
18. Gollin G, Ward B, Meier GH, Sumpio BE, Gusberg RJ. Central splanchnic vein thrombosis: often unsuspected, usually uncomplicated. J Clin Gastroenterol 1994;18:109-13.
19. Ronchetto F. Occlusion of a branch of the central retinal vein as a manifestation of hypercoagulability in a patient with lung cancer. A possible paraneoplastic event. Recenti Prog Med 1994;85:108-12.
20. DeCross AJ, Sahasrabudhe DM. Paraneoplastic Raynaud's phenomenon. Am J Med 1992;92:570-2.
21. Naschitz JE, Schechter L, Chang JB. Intermittent claudication associated with cancer - case studies. Angiology 1987;9: 696-704.
22. Naschitz JE, Yeshurun D, Abrahamson J, Eldar S, Chouri H, Kedar S, et al. Ischemic heart disease precipitated by occult cancer. Cancer 1992;69:2712-20.
23. Francis JL. Haemostasis and cancer. Med Lab Sci 1989;46: 331-6.
24. Messmore H, Nand S. Hemostasis in malignancy. Am J Hematol 1990;35:45-55.
25. Edwards RL, Rickles FR. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
26. Gore JM, Appelbaum JS, Greene HL, Dexter JE. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982;96:556-60.
27. Helin H. Macrophage procoagulant factors: mediators of inflammatory and neoplastic tissue lesions. Med Biol 1986;64: 167-76.
28. Pacchiarini L, Melloni F, Zucchella M, Mangiarotti P, Tacconi F, Ballabio P, et al. Proaggregating and procoagulant activities of human mesothelioma tumor cells at different stages of "in vitro" culture. Haematologica 1991;76:392-7.
29. Grignani G, Jamieson GA. Platelets in tumor metastasis: generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential. Blood 1988;71:849-55.
30. Grignani G, Pacchiarini L, Ricetti MM, Dionigi P, Jemos V, Zucchella M, et al. Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metastasis 1989;9:298-309.
31. Zucchella M, Dezza L, Pacchiarini L, Meloni F, Tacconi F, Bonomi E, et al. Human tumor cells cultured "in vitro" activate platelet functions by producing ADP or thrombin. Haematologica 1989;74:541-5.
32. Kozwich DL, Kramer LC, Mielicki WP, Fotopulos SS, Gordon SG. Application of cancer procoagulant as an early detection tumor marker. Cancer 1994;74:1367-76.
33. Cross BA, Gordon SG. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 1990;50:6229-34.
34. Benson BA, Gordon SG. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989;56:431-40.
35. Al-Mondhiry H, McGarvey V. Tumor interaction with vascular endothelium. Haemostasis 1987;17:245-53.
36. Bastida E, Ordinas A. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis 1988;18:29-36.
37. Moake JL. Hypercoagulable states. Adv Intern Med 1990;35: 235-48.
38. Naschitz JE, Yeshurun D, Lev LM. Thromboembolism in cancer. Changing trends. Cancer 1993;71:1384-90.
39. Vales O, Warren B. The adhesion of thromboplastic tumor emboli to vessel wall in vitro. Br J Exp Pathol 1972;53:301-13.
40. Higgs EA, Moncada S. Prostacyclin: physiology and clinical uses. Gen Pharmacol 1983;14:7-11.
41. Mendelsohn ME, Loscalzo JL. The endotheliopathies. Loscalzo JL, Creager MA, Dzau VJ, editors. Vascular medicine. A textbook of vascular biology and diseases. Boston: Little, Brown and Company, 1992:279-303.
42. Conger JD. Endothelial regulation of vascular tone. Hosp Pract 1994:117-26.
43. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1985;53:127-32.
44. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-20.
45. Balleisen L, Schulte H, Assman G, Epping PH, Van De Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987;1:462-7.
46. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995;332:677-8.
47. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischemic heart disease: principle results of the Northwick Park Health Study. Lancer 1986;2:533-7.
48. Wilhelmsen L, Svardsud K, Korsan-Bengsten K, Larsson B, Tibblin G. Fibrinogen as a cardiovascular risk factor for stroke and myocardial infarction. N Engl J Med 1984;311: 501-5.
49. Yarnell JWG, Baker JA, Sweetnam PM, Bainton O, O'Brien JR, Whitehead PJ. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991;83:836-44.
50. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1991;9(Suppl):3-9.
51. Gasic GJ, Catalfamo JL, Gasic TB, Advalovic N. In vitro mechanism of platelet aggregation by purified plasma membrane vesicles shed by mouse 15091 A tumor cells. Donati I, editor. Malignancy and the haemostatic system. New York: Raven Press, 1981:27-33.
52. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer: mononuclear cell tissue factor generation. J Lab Clin Med 1981;98:917-28.
53. Maruyama M, Yagawa K, Hayashi S, Kinjo M, Nakanishi M, Ogata K, et al. Presence of thrombosis-inducing activity in plasma from patients with lung cancer. Am Rev Resp Dis 1989;140:778-81.
54. Van de Water L, Tracy PB, Aranson D, Mann KG, Dvorak F. Tumor cell generation of thrombin via prothrombinase assembly. Cancer Res 1985;45:5521-5.
55. Bona RD, Dhami MS. Thrombosis in patients with cancer. Postgrad Med 1993;93:131-40.
56. Hill VA, Whittaker SJ, Hunt BJ, Liddell K, Spittle MF, Smith NP. Cutaneous necrosis associated with antiphospholipid syndrome and mycosis fungoides. Br J Dermatol 1994;130: 92-6.
57. Damus PS, Wallace GA. Immunologic measurement of anti-thrombin III, heparin cofactor and alpha-2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 1976;5:27-38.
58. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, et al. Preliminary study to identify cancer patients at risk of venous thrombosis following major surgery. Br J Haematol 1993;85:745-50.
59. Moore KL, Esmon CT, Esmon H. Tumor necrosis factor leads to internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159-65.
60. Carnella F, Fetoni V, Pollo B, Testa D, Tagliavini F, Girotti F. Sneddon's syndrome and renal cell carcinoma. Case report. Funct Neurol 1992;7:395-400.
61. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-4.
62. Kozlowski CL, Johnson MJ, Gorst DW. Lung cancer, immune thrombocytopenia and the lupus inhibitor. Postgrad Med J 1987;63:793-5.
63. Levine SR, Diaczok IM, Deegan MJ, Kieran SN, Feit H, Elias SB, et al. Recurrent stroke associated with thymoma and anticardiolipin antibodies. Arch Neurol 1987;44:678-9.
64. Zuckerman E, Toubi E, Golan TD, Rosenvald-Zuckerman T, Sabo E, Shmuel Z, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995;72:447-51.
65. Katherdahl DA. Calf pain mimicking thrombophlebitis. Postgrad Med J 1980;68:107-15.
66. Naschitz JE, Yeshurun D, Gaitini D. Deep venous leg thrombosis and its differential diagnosis: the case for B-mode ultrasonography. Int J Angiology 1993;1:218-24.
67. Zorba J, Schrier D, Posmituck G. Clinical value of blood pool radionuclide venography. AJR Am J Roentgenol 1985;146: 1051-5.
68. Koopman MMW, Beek EJR, ten Cate JW. Diagnosis of deep vein thrombosis. Prog Cardiovasc Dis 1994;37:1-12.
69. Cronan JJ. Ultrasound evaluation of deep venous thrombosis. Semin Roentgenol 1992;27:39-52.
70. Evans AJ, Sostman HD, Knelson MH, Spritzer CE, Newman GE, Paine SS, et al. Detection of deep venous thrombosis: prospective comparison of MR imaging with contrast venography. AJR Am J Roentgenol 1993;161:131-9.
71. Goldhaber CZ, Dricker E, Buring JE, Eberlein K, Godleski JJ, Mayer RJ, et al. Clinical suspicion of autopsy-proven thrombotic and tumor embolism in cancer patients. Am Heart J 1989;114:1432-6.
72. Raad II, Luna M, Khalil AM, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994;271: 1014-6.
73. Galli R, Parlapiano M, Pace Napoleone C, Pierangelli A. Neoplastic caval and intracardiac thrombosis secondary to reno-adrenal tumors. One-stage surgical treatment in deep hypothermia and cardiocirculatory arrest. Minerva Urol Nefrol 1994;46:105-11.
74. Mitchell MC, Boitnott JK, Kaufman S, Cameron JL, Maddrey WC. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 1982;61:199-218.
75. Fogteloo AJ, Smid WM, Kok T, Van-Der-Meer J, Van-Imhoff GW, Daenen S. Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin's lymphoma. Leukemia 1993;7:760-3.
76. Chaikoff EL, Campbell BE, Smith RB 3d. Paradoxical embolism and acute arterial occlusion: rare or unsuspected? J Vasc Surg 1994;20:377-84.
77. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke 1994;25:1215-8.
78. Taylor LM, Hauty MG, Edwards JM. Digital ischemia as a manifestation of malignancy. Ann Surg 1983;206:62-8.
79. Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med 1989;149:105-9.
80. Tallman MS, Hakimian D, Kwaan HC, Rickles FR. New insights into the pathogenesis of coagulation dysfunction in acute pro-myelocytic leukemia. Leuk Lymphoma 1993;11:27-36.
81. Naschitz JE, Rosner I, Rozenbaum M, Elias N, Yeshurun D. Cancer-associated rheumatic disorders: clues to occult neoplasia. Semin Arthritis Rheum 1995;24:231-41.
82. Gabriel S, Conn D, Phyliky RL, Pittelkow MR, Scott RE. Vasculitis in hairy cell leukemia: review of the literature and consideration of possible pathogenic mechanisms. J Rheumatol 1986;13:1167-72.
83. Cupps TR, Fauci AS. The vasculitides. Philadelphia: WB Saunders, 1981:116-8.
84. Mitchell DM, Hoffbrand BI. Relapse of Henoch-Schonlein disease associated with lung carcinoma. J R Soc Med 1979;72:614-5.
85. Sulkes A, Naparstek Y. The infrequent association of systemic lupus erythematosus and solid tumors. Cancer 1991;68:1389-93.
86. Case Records of the Massachusetts General Hospital. N Engl J Med 1990;322:1656-65.
87. Alarcon-Segovia D, Babb RR, Fairbairn JH 2d, Hagedorn AB. Erythermalgia. A clue to the early diagnosis of myeloproliferative disorders. Arch Intern Med 1966;117:511-15.
88. Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol 1983;14:155-67.
89. Wytock DH, Bartholomew LG, Sheps S. Digital ischemia associated with small bowel malignancy. Gastroenterology 1983;84:1025-7.
90. Naschitz JE, Yeshurun D, Abrahamson J. Arterial occlusive disease in occult cancer. Am Heart J 1992;124:738-45.
91. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, et al. Effect of warfarin on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984;53:2046-52.
92. Zacharski LR, Moritz TE, Baczek LA, Rickles FR, Edwards RL, Forman WB, et al. Effect of Mopidamol on survival of carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No 188. J Natl Cancer Inst 1988;80:90-7.
93. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602.
94. Mertz LE, Conn DL. Vasculitis associated with malignancy. Curr Opin Rheumatol 1992;4:90-3.
95. Naschitz JE, Yeshurun D, Abrahamson J. Incidence and diagnostic significance of paraneoplastic thromboembolic disorders. Int Angiol 1989;8:28-31.
96. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
97. Nordstrom M, Lindblad B, Anderson H, Bergguist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study BMJ 1994;308:891-4.
98. McKenna MT. Deep venous thrombosis and the risk of cancer. Arch Intern Med 1989;149:966-7.
99. O'Connor N. Venous thrombosis and cancer [letter]. N Engl J Med 1993;328:886-9.
100. O'Connor NTJ, Cederholm-Williams SA, Fletcher EW, Allington M, Sharp AA. Significance of idiopathic deep venous thrombosis. Postgrad Med 1984;60:275-7.
101. Naschitz JE, Yeshurun D, Abrahamson J. Thromboembolism. Clues for the presence of occult neoplasia. Int Angiol 1989;8:200-5.
102. Ekenstam E, Callen JP. Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen at a private praxis. Arch Dermatol 1984;120:484-9.
103. Rickles FR, Levine MN, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;1:241-60.
104. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993;70:540-2.
105. Gaddiucci A, Baicchi U, del Bravo B, Marrai R, Vispi M, Fioretti P. The assessment of the hemostasis system in patients with ovarian and cervical carcinoma. Cancer 1991;4:183-7.
106. Monreal M, Lafoz E, Casals A. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 1990;67:541-5.
107. Callandar N, Rappaport SI. Trousseau's syndrome. West J Med 1993;158:364-71.
108. Silverstein R, Nachman RL. Cancer and clotting - Trousseau's warning. N Engl J Med 1992;327:1163-4.
109. Rapaport SI. Blood coagulation and its alterations in hemorrhagic and thrombotic disorders. West J Med 1993;158:153-61.
110. Tisdale JE, Snowden TR, Johnson DR. Case report: poorly differentiated carcinoma of unknown primary presenting as Trousseau's syndrome. Am J Med Sci 1995;309:183-7.